London, United Kingdom | November 18, 2026
French animal health major Virbac has outlined its medium-term strategic priorities at the Jefferies Global Healthcare Conference in London, reaffirming its ambition to achieve a 20% adjusted EBITDA margin by 2030.
The company’s strategy combines three principal growth drivers:
-
Consistent organic outperformance against the animal health market.
-
Selective bolt-on acquisitions to strengthen strategic product platforms.
-
Operational improvements and margin expansion to support long-term profitability.
The conference discussion also provided insight into Virbac’s investment priorities, manufacturing strategy and appetite for acquisitions in an increasingly competitive global veterinary pharmaceutical market.
Virbac’s 2030 ambition: A 20% adjusted EBITDA margin
One of the most important strategic targets reiterated at the conference was the company’s ambition to reach a 20% adjusted EBITDA margin by 2030. The progression implies an improvement in profitability while the company continues to invest in R&D, product innovation, geographic expansion and manufacturing infrastructure.
The strategy is not simply to reduce expenditure. Instead, Virbac wants to generate sufficient productivity and gross-margin improvement to finance continued growth.
Seven Supercharge platforms: The engine of organic growth
Virbac’s seven Supercharge platforms form a central part of its medium-term strategy. These platforms are intended to concentrate commercial, R&D and geographic investment in product categories where the company believes it can achieve sustainable growth and competitive differentiation.
Management indicated that the platforms currently represent approximately 40% of company sales, while the particularly high-growth portfolio discussed in the presentation represented approximately 14%.
This distinction is important: the 14% figure should not be confused with the total contribution of all seven platforms. Management expects the Supercharge platforms to continue growing at double-digit rates for several years.
The strategy is based on combining internal innovation with external licensing, technology partnerships and targeted acquisitions.
Virbac raises confidence in its 2026 revenue outlook
The company reported approximately 8% growth through September 2026. Management indicated that this performance supports targeting the upper end of its previously announced full-year revenue growth guidance.
| Financial indicator | Management outlook |
|---|---|
| 2026 revenue growth guidance | 5.5–7.5% |
| Growth through September | Approximately 8% |
| Full-year target | Upper end of guidance |
| 2026 adjusted EBITDA margin | Approximately 17% |
| 2030 adjusted EBITDA margin ambition | 20% |
The figures refer to growth at constant exchange rates and scope where applicable. The company attributed its performance to the strength of its strategic product platforms, geographical expansion and continued commercial execution.
Selective M&A: Virbac remains interested in smaller strategic acquisitions
An important message from the conference was that Virbac remains open to acquisitions. Management highlighted the fragmented structure of the global animal health industry, where numerous smaller businesses possess valuable technologies, brands and specialised product portfolios but lack the resources to scale internationally. Virbac sees opportunities to provide these companies with access to:
-
International distribution.
-
Regulatory expertise.
-
Manufacturing capabilities.
-
Commercial infrastructure.
-
R&D resources.
-
Established veterinary relationships.
Management discussed potential transactions in the approximate €10–20 million range as capable of being strategically attractive. The acquisition approach is selective and case-specific, rather than a strategy of pursuing large transactions for scale alone.
Previous acquisitions and strategic additions Virbac discussed its previous acquisitions, including:
-
Thyronorm, strengthening its US specialty endocrinology portfolio.
-
A Japanese acquisition supporting its ruminant and vaccine positioning.
The company has also expanded its product portfolio through licensing and internal development. This combination allows Virbac to build specialised product categories without relying exclusively on expensive internal research programmes.
Manufacturing transformation: 25 global sites under strategic review
Manufacturing and industrial productivity are important components of Virbac’s profitability strategy. Management highlighted its global manufacturing footprint of approximately 25 sites. The company is reviewing which facilities should become core strategic manufacturing locations and where further investment can deliver improved productivity.
Virbac expects 2026 capital expenditure of approximately €125 million, reflecting substantial investment in industrial transformation. Management also discussed the planned closure of one Australian site at the end of 2027 as part of longer-term manufacturing optimisation.
This should be understood as a specific restructuring measure within a broader operational strategy rather than evidence of a general withdrawal from the Australian market. The company’s focus is on creating a more efficient manufacturing network that supports growth beyond 2030.
R&D remains a significant investment priority
Virbac indicated that annual R&D spending is approximately 8% of revenue. The company has introduced 20 new products over the previous three years, with recent examples covering:
-
Mobility products.
-
Ruminant vaccines.
-
Long-acting parasiticides.
-
Companion animal ear-health products.
The company is balancing internal R&D with commercial licensing, technology licensing and M&A. This is particularly important in an industry where specialised veterinary technologies can be developed by smaller biotechnology businesses but require global commercial infrastructure to achieve meaningful market penetration.
Why Virbac’s strategy matters to the global animal health industry
Virbac’s conference presentation provides several insights into the direction of the veterinary pharmaceutical industry.
First, organic growth remains the foundation – The company wants to outperform the overall animal health market through product innovation, commercial execution and geographical expansion.
Second, acquisitions are becoming more targeted – Rather than relying only on large-scale consolidation, established businesses can acquire smaller specialised companies to strengthen individual therapeutic categories.
Third, operational excellence is becoming a competitive differentiator – Manufacturing efficiency and productivity are increasingly important in protecting margins while maintaining R&D investment.
Fourth, companion and farm animal markets continue to provide complementary growth opportunities – Virbac’s long-term outlook reflects the medicalisation of companion animals and the structural importance of animal protein production.
What to monitor next
| Strategic area | Key indicator |
|---|---|
| Organic growth | Full-year 2026 revenue performance |
| Supercharge platforms | Sustained double-digit growth |
| M&A | New bolt-on acquisitions |
| R&D | New product introductions |
| Manufacturing | Progress on industrial transformation |
| Profitability | Gross-margin improvement |
| Capital expenditure | Delivery of 2026 investment programme |
| 2030 ambition | Progress towards 20% adjusted EBITDA margin |

